Compare CVS Health Corp (CVS) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Freeport-McMoRan Inc — how do they compare? CVS Health Corp trades at $106.43 (market cap $135.48B), while Freeport-McMoRan Inc trades at $60.61 (market cap $89.06B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | FCX | |
|---|---|---|
Market Cap | $135.48B | $89.06B |
Sector | Health | Basic Materials |
52-Week High | $106.18 | $71.73 |
52-Week Low | $58.75 | $35.34 |
Enterprise Value | $202.02B | $95.72B |
Dividend Yield | 2.51% | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
FCX trades at $59.98, down 2.51% today, with a bearish technical signal but strong fundamentals. Recent earnings beats and a 10.34% net income margin highlight operational strength. The stock faces near-term resistance at $61, with support at $59. Analysts maintain a $72.94 consensus target, reflecting 22% upside potential. Copper demand growth and expansion projects support long-term prospects.
Outlook remains positive driven by copper's structural supply-demand imbalance and FCX's cost leadership. Risks include commodity price volatility and execution challenges in new projects. Institutional sentiment is bullish with 59% buy ratings, though technical indicators suggest near-term consolidation. The dividend yield of 0.25% provides modest income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
